Myasthenia Gravis News and Research

RSS
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Symptoms vary in type and severity. Myasthenia gravis is not directly inherited nor is it contagious.
Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

Nanoscientist to develop new microsystem for more efficient drug-testing

Nanoscientist to develop new microsystem for more efficient drug-testing

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

U.S. FDA approves generic Levaquin for treatment of bacterial infections

U.S. FDA approves generic Levaquin for treatment of bacterial infections

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi launches CUVPOSA for pediatric chronic severe drooling

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Geisinger Medical Center performs first transcervical thymectomy

Geisinger Medical Center performs first transcervical thymectomy

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.